Innovations in the systemic therapy of prostate cancer
- 8 December 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 7 (1), 13-21
- https://doi.org/10.1038/nrclinonc.2009.187
Abstract
Systemic therapy has become an increasingly important component of treatment of advanced prostate cancer. In the past decade, important innovations have been achieved in the development of novel systemic hormonal therapies for the salvage treatment of metastatic castrate-resistant disease. These improvements have been accompanied by the broadening of potential indications for chemotherapy in castrate-resistant metastatic disease and the use of chemotherapy as an adjunct to the treatment of locally extensive tumors. These changes have begun to lead to improved outcomes, but at the expense of novel patterns of late toxic effects. We review the key steps in the recent evolution of systemic therapy of prostate cancer.Keywords
This publication has 86 references indexed in Scilit:
- Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31Journal of Clinical Oncology, 2009
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancerCancer, 2008
- Diabetes and Mortality in Men With Locally Advanced Prostate Cancer: RTOG 92-02Journal of Clinical Oncology, 2008
- Falls and Physical Performance Deficits in Older Patients With Prostate Cancer Undergoing Androgen Deprivation TherapyUrology, 2008
- Neoadjuvant Docetaxel and Capecitabine in Patients With High Risk Prostate CancerJournal of Urology, 2008
- Antiandrogen withdrawal in castrate‐refractory prostate cancerCancer, 2008
- Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate CancerUrology, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Anthracyclines, Mitoxantrone, Radiotherapy, and Granulocyte Colony-Stimulating Factor: Risk Factors for Leukemia and Myelodysplastic Syndrome After Breast CancerJournal of Clinical Oncology, 2007
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006